Objectives: We investigated statin therapy could be beneficial in patients with acute myocardial infarction (AMI) who have baseline low density lipoprotein-cholesterol (LDL-C) levels below 70 mg/dL. Background: Intensive lipid lowering therapy with target value of LDL-C less than 70 mg/dL is recommended in patients with very high cardiovascular risk. However, whether to use statin in patients with baseline LDL-C levels below 70 mg/dL is controversial. Methods: We analyzed 1,054 AMI patients who had baseline LDL-C levels below 70 mg/dL and survived at discharge from Korean Acute MI Registry (KAMIR) between November 2005 and December 2007. They were divided to two groups according to the prescription of statin at discharge (Statin group; n=607, Non-statin group; n=447). The primary end point was the composite of 1-year major adverse cardiac events including death, recurrent myocardial infarction (MI), target vessel revascularization and coronary artery bypass grafting. Results: Statin therapy significantly reduced the risk of the composite the primary end point (adjusted hazard ratio [HR] 0.56, 95% confidence interval [CI] 0.34-0.89, p=0.015). Statin therapy reduced the risk of cardiac death (HR 0.47, 95% CI 0.23-0.93, p=0.031) and coronary revascularization (HR 0.45, 95% CI 0.24-0.85, p=0.013). However, there were no differences in the risk of the composite of all-cause death, recurrent MI, and repeated percutaneous coronary intervention rate. Conclusions: AMI patients with LDL-C levels below 70 mg/dL may still derive benefit from statin therapy.